Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
6MW3211 in Advanced Lung Cancer Post-PD-1/L1 Failure
NCT05431569Phase 2Unknown
- Sponsor
- Mabwell
- Start
- Jul 2022
- Primary completion
- Dec 2022
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of 6MW3211 in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), sponsored by Mabwell. Primary endpoint: Objective Response Rate up to 24 months. Status: unknown.
02
Drugs
6MW3211
03
Conditions
non-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT05431569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05431569.